PUBLICACIONES

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial
Source: Alberto Borobia Published on 2024-11-07
Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial
Source: Alberto Borobia Published on 2024-11-07
Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial
Source: Alberto Borobia Published on 2024-11-07
Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial
Source: Alberto Borobia Published on 2024-11-07
Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial
Source: Alberto Borobia Published on 2024-11-07
Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial
Source: Alberto Borobia Published on 2024-11-07
Dubbing language-therapy CINEma-based in aphasia post-stroke (DULCINEA): A feasibility randomized crossover controlled trial
Source: Alberto Borobia Published on 2024-10-18
Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants
Source: Alberto Borobia Published on 2024-09-17
Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study
Source: Alberto Borobia Published on 2024-05-30
ALDRESS: A Retrospective Pilot Study to Develop a Pharmacological Causality Algorithm for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Source: Alberto Borobia Published on 2024-05-11
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study
Source: Alberto Borobia Published on 2024-05-05
Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2
Source: Alberto Borobia Published on 2024-02-20
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19
Source: Alberto Borobia Published on 2024-02-20
Developments in pharmacogenetics, pharmacogenomics, and personalized medicine
Source: Alberto Borobia Published on 2024-01-10
Implementing pharmacogenetics in clinical trials: considerations about current methodological, ethical, and regulatory challenges
Source: Alberto Borobia Published on 2023-12-13

Hospital Universitario La Paz

Servicio de Farmacología Clínica – UCICEC

Horario:

Lunes a Jueves 8.00-17.00

Viernes 8.00 - 15.00

Teléfono: 91 207 14 66

Fax: 91 207 13 84

Email: ucicec.hulp@salud.madrid.org